Nu Holdings just delivered the earnings beat that two consecutive previews warned might not come — and the resulting squeeze of defensively positioned options traders amplified a 12% single-day move that carried the stock to $15.23.
The options picture reversed violently. The previous earnings preview flagged a put/call ratio of 0.69, nearly three standard deviations above its 20-day mean — the most defensive read in almost a year. That hedging demand became a tailwind on the way up. After the print, the PCR closed at 0.69 on August 14, still well above its 20-day average of 0.57 and just below the 52-week high of 0.76. At nearly three standard deviations elevated, the options market remains more guarded than usual even after the pop — suggesting some traders are still paying for protection rather than chasing the move outright.
Short positioning tells a much calmer story, and that divergence matters for understanding this week's setup. Short interest has fallen more than 11% over the past month to 3.7% of the float, continuing a steady unwind from the mid-July peak near 160 million shares borrowed. The borrow market is among the loosest on the exchange: availability is running near 2,236%, meaning there are roughly twenty-two shares available to lend for every one already borrowed. Cost to borrow is just 0.41%, down 31% over the week. There was no short-squeeze dynamic driving the post-earnings move — shorts were already departing before the result came in.
The Street had been split heading into the release, and the cleaner-than-expected number is prompting a rapid re-rating. Susquehanna raised its target to $16 from $13 on August 14, maintaining Neutral. Needham lifted to $19 from $17, keeping its Buy. JP Morgan had already moved to $20 in July with an Overweight. The consensus mean target is now $18.25, implying about 20% further upside from current levels. That contrasts sharply with the Citigroup downgrade to Neutral at $13 and the BofA Underperform call at $10 from early June — both of which now look well offside. EPS momentum factors rank in the 81st percentile on a 30-day basis and the 85th on 90 days, suggesting the estimate-revision cycle has been running hotter than the stock's prior price action implied.
The institutional holder base adds a notable dimension. Founder and CEO David Velez holds 18.8% of shares. BlackRock added 16.4 million shares through July 31. Capital Research added more than 20 million shares in the same period. JP Morgan Asset Management added 13 million. These are not marginal flows — three of the top ten holders were active buyers heading into the result. The insider picture is less constructive in isolation: Velez, co-founder Cristina Junqueira, and the Chief Risk Officer all ran small pre-planned sells in July at $13.39, well below Thursday's close. Those transactions are routine in scale but worth noting given the gap between sale price and current market.
The next earnings event is not until November 12 — giving the stock roughly 13 weeks to trade on the fundamental story rather than event risk. The question worth watching is whether the Street's remaining bears, particularly BofA at a $10 Underperform, move to close the gap, and whether the post-earnings options defensiveness fades as hedges roll off or persists into new uncertainty about whether this quarter's beat marks a trend change or a single clean print.
See the live data behind this article on ORTEX.
Open NU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
